8-K: Cidara Reports Q3 2025 Results, Accelerates CD388 Phase 3

Cidara Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting an expanded and accelerated Phase 3 plan for its influenza preventative therapeutic, CD388.

Summary

• Net loss for the third quarter ended September 30, 2025, was $83.2 million, compared to a net loss of $16.0 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $132.4 million, compared to $117.5 million for the same period in 2024.
• Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $476.5 million as of September 30, 2025, a significant increase from $196.2 million as of December 31, 2024.
• Acquired in-process research and development (IPR&D) expenses were $45.0 million for Q3 2025, related to a milestone payment incurred under the Janssen License Agreement upon dosing the first five subjects in the ANCHOR study.
• Research and development (R&D) expenses increased to $35.5 million for Q3 2025 from $12.4 million for Q3 2024, primarily due to higher CD388 manufacturing costs and the initiation of the ANCHOR study.
• General and administrative (G&A) expenses were $8.1 million for Q3 2025, up from $5.0 million for Q3 2024, mainly due to higher personnel costs and stock-based compensation.
• The Phase 3 ANCHOR study for CD388 is over 50% enrolled, with target enrollment of 6,000 participants expected to be completed by December 2025 in the Northern Hemisphere.
• The FDA granted Breakthrough Therapy designation to CD388 in October 2025, following positive results from the Phase 2b NAVIGATE study.
• The Biomedical Advanced Research and Development Authority (BARDA) awarded up to $339.2 million, with initial funding of $58.1 million over 24 months, to support onshoring of CD388 manufacturing and clinical development.
• The ANCHOR study population was expanded to include generally healthy adults over the age of 65, in addition to individuals with comorbidities, potentially increasing the eligible U.S. population for CD388 from approximately 50 million to over 100 million people.

Sentiment

Score: 7

Explanation: While financial losses increased significantly due to R&D and milestone payments, the substantial cash balance, accelerated Phase 3 progress for CD388, Breakthrough Therapy designation, and a large BARDA award represent strong positive developments for the company's core asset and future prospects. The increased burn is largely attributable to advancing a high-potential program.

Positives

• A strong cash position of $476.5 million as of September 30, 2025, which is expected to fully fund the Phase 3 development program through completion.
• CD388 received Breakthrough Therapy designation from the FDA in October 2025, which is intended to expedite the review of medicines for serious conditions with potential for substantial improvement.
• The BARDA award of up to $339.2 million, with $58.1 million in base funding, will support expanded manufacturing and clinical development of CD388, including onshoring manufacturing to the U.S.
• The Phase 3 ANCHOR study for CD388 is over 50% enrolled, with target enrollment of 6,000 participants on track for completion by December 2025 in the Northern Hemisphere.
• The ANCHOR study population was expanded to include generally healthy adults over 65, potentially more than doubling the target eligible U.S. population for CD388 from 50 million to over 100 million people.
• Positive results from the Phase 2b NAVIGATE study showed CD388 was well-tolerated and met all primary and secondary endpoints in preventing seasonal influenza in healthy unvaccinated adults.
• The company is proceeding with an expanded and accelerated development plan to seek biologics license application (BLA) approval based on a single Phase 3 study for CD388.

Negatives

• Net loss for Q3 2025 significantly increased to $83.2 million, compared to $16.0 million in Q3 2024.
• Research and development expenses rose substantially to $35.5 million in Q3 2025 from $12.4 million in Q3 2024, driven by increased CD388 manufacturing and ANCHOR study costs.
• General and administrative expenses increased to $8.1 million in Q3 2025 from $5.0 million in Q3 2024, primarily due to higher personnel costs and stock-based compensation.
• Incurred $45.0 million in acquired IPR&D expenses in Q3 2025 for a milestone payment to Janssen related to the ANCHOR study.
• Collaboration revenue was zero for Q3 2025, down from $1.3 million for the nine months ended September 30, 2024, due to the termination of the Janssen Collaboration Agreement.

Risks

• Unanticipated delays in or negative results from clinical studies.
• Risks related to clinical development generally.
• Delays in or unanticipated action by regulatory authorities.
• Other obstacles associated with participant enrollment or other aspects of CD388 or other DFC development.
• Risks related to government contracts.
• Having to use cash in ways other than as expected.
• General business risks and uncertainties.

Future Outlook

Cidara expects to achieve target enrollment of 6,000 participants for the Phase 3 ANCHOR study by December 2025, with an interim analysis planned for the first quarter of 2026. The company anticipates that its strong balance sheet, bolstered by a recent financing, will be sufficient to fully fund the Phase 3 development program through completion. They aim to seek biologics license application (BLA) approval for CD388 based on a single Phase 3 study, potentially for a broader patient population including otherwise healthy adults over 65.

Management Comments

• "With our Phase 3 ANCHOR study now over 50 percent enrolled, we expect to achieve target enrollment of 6,000 participants by December 2025 and thereby advance CD388 as a potential universal preventative for people at increased risk of complications from influenza as well as those seeking alternatives to flu vaccines."
• "Based on constructive feedback from the FDA, the ANCHOR study population has been expanded to include generally healthy adults over the age of 65 in addition to individuals with certain comorbidities or compromised immune status. This change more than doubles the target population potentially eligible to receive CD388."
• "Our successful financing this summer has provided us with a strong balance sheet that we expect to be sufficient to fully fund our Phase 3 development program through completion."

Industry Context

The expansion of the CD388 ANCHOR study to include healthy adults over 65 and the Breakthrough Therapy designation highlight a growing industry focus on broad-spectrum, non-vaccine preventative therapeutics for infectious diseases like influenza, especially for vulnerable populations and those seeking alternatives to traditional vaccines. The BARDA award also underscores government interest in supporting domestic manufacturing and development of critical public health countermeasures.

Comparison to Industry Standards

• The Breakthrough Therapy designation for CD388 indicates that the FDA believes it may offer a substantial improvement over available therapies for a serious condition, placing it in a category with other high-potential drug candidates that receive expedited review.
• The BARDA award of up to $339.2 million for CD388 manufacturing and development is a significant government investment, comparable to funding provided for other critical public health initiatives and pandemic preparedness efforts, signaling strong external validation of the program's importance.
• Expanding the target population for CD388 to over 100 million people in the U.S. (including healthy adults over 65) positions it for a market opportunity that rivals or exceeds many established seasonal flu vaccine markets, which typically target specific age groups or risk profiles.

Related Party Transactions

• A $45.0 million milestone payment incurred under the Janssen License Agreement, upon dosing the first five subjects in the ANCHOR study, will be paid to Janssen in the fourth quarter of 2025.
• Acquired IPR&D in 2024 related to an upfront payment of $85.0 million paid to Janssen under the Janssen License Agreement on April 24, 2024, in connection with the re-acquisition of CD388, plus $0.4 million in direct transaction costs, offset by a gain of $0.5 million to settle the preexisting Janssen Collaboration Agreement relationship.

Stakeholder Impact

• Shareholders: Potential for significant value creation if CD388 successfully completes Phase 3 and gains approval, given its Breakthrough Therapy designation and large market potential. Increased net loss and R&D expenses reflect investment in this key asset. Strong cash position reduces immediate dilution risk.
• Patients (especially high-risk and elderly): Potential for a novel, universal preventative therapeutic for influenza, offering an alternative to vaccines and addressing a significant unmet medical need.
• Employees: Continued development and manufacturing activities for CD388 suggest stable or growing employment opportunities, particularly with the onshoring of manufacturing.
• Janssen: Receipt of a $45.0 million milestone payment in Q4 2025.
• U.S. Government (BARDA): Investment in a promising therapeutic for public health preparedness and domestic manufacturing capabilities.

Next Steps

• Complete target enrollment of 6,000 participants for the Phase 3 ANCHOR study by December 2025.
• Conduct an interim analysis for the ANCHOR study in the first quarter of 2026 to assess trial size and powering assumptions.
• Determine the potential need for additional enrollment during the subsequent Southern Hemisphere flu season based on interim analysis.
• Onshore CD388 manufacturing to the U.S. using BARDA funding.
• Pay the $45.0 million milestone to Janssen in the fourth quarter of 2025.
• Advance CD388 towards BLA approval based on a single Phase 3 study.

Key Dates

Recommendation

Despite a significant increase in net loss, the underlying operational developments are highly positive and de-risking for Cidara's lead asset, CD388. The substantial cash balance of $476.5 million, secured through a recent financing, provides ample runway to fund the critical Phase 3 program through completion. The FDA's Breakthrough Therapy designation and the large BARDA award (up to $339.2 million) are strong validations of CD388's potential and strategic importance. Expanding the ANCHOR study population to include healthy adults over 65 significantly broadens the market opportunity. These factors collectively suggest a strong long-term growth trajectory and a favorable risk-reward profile for investors, outweighing the short-term increase in R&D expenses which are necessary investments for advancing a late-stage clinical program.

Keywords

Cidara Therapeutics, CDTX, CD388, Influenza, Antiviral, Phase 3, ANCHOR study, Breakthrough Therapy, FDA, BARDA, Financial Results, Q3 2025, Biotechnology, Drug-Fc Conjugate, DFC, Clinical Trials, Preventative Therapeutic